Incyte Corporation

INCY

US45337C1027

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

15/05/2024 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 03:00 pm

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.06 USD

Average target price

73.35 USD

Spread / Average Target

+38.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.27%	11.91B
CSL LIMITED	-2.35%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.9B
BIOGEN INC.	-12.92%	32.25B
UCB	+54.69%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-16.51%	15.39B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.34%	9.03B
INNOVENT BIOLOGICS, INC.	-7.60%	8.62B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
57.6 ^USD	+8.56%		+6.51%	-8.27%

05-13	Equities Close Mixed as Markets Weigh Consumer Inflation Survey	MT
05-13	Equities Close Mixed as Markets Parse Consumer Inflation Survey	MT

Equities Close Mixed as Markets Weigh Consumer Inflation Survey	05-13	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	05-13	MT
Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey	05-13	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	05-13	MT
Increasing Short-Term Inflation Expectations Weigh on US Equity Indexes Ahead of Consumer, Producer Prices	05-13	MT
US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase	05-13	MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday	05-13	MT
Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares	05-13	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
TD Cowen Adjusts Price Target on Incyte to $80 From $88	05-01	MT
RBC Capital Adjusts Price Target on Incyte to $60 From $65	05-01	MT
Piper Sandler Adjusts Price Target on Incyte to $80 From $85	05-01	MT
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63	05-01	MT
Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating	05-01	MT
Citigroup Adjusts Price Target on Incyte to $80 From $81	05-01	MT
BMO Capital Adjusts Incyte Price Target to $52 From $56	05-01	MT
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained	04-30	MT
Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	04-30	MT
Transcript : Incyte Corporation, Q1 2024 Earnings Call, Apr 30, 2024	04-30
Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M	04-30	MT
Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83	04-30	MT
Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
Incyte Corporation Maintains Revenue Guidance for 2024	04-30	CI
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	04-24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	04-23